However with 3 now consecutive successful Phase 2 and Phase 3 positive result studies done with this technology/device....can you imagine what NVCR would be if the FDA finally approved the TTF technology for treatments? They now have the technology and data to put pressure on the FDA for TTF Treatment approvals it looks like.
$NVCR unlike a lot of under $10 pharms is not a one-trick pony per say....they have several phase studies in the pipeline and the brain cancer treatment phase 3 study/results yesterday were very positive and encouraging and will gain support now as the news articles state.
I would NOT be surprised now after the results of the 3 studies that something very soon gets Fast Tracked by the FDA.
JMO
Recent NVCR News
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon • Business Wire • 05/02/2024 11:01:00 AM
- Novocure Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 11:00:00 AM
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 • Business Wire • 04/24/2024 02:45:00 PM
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 • Business Wire • 04/05/2024 11:00:00 AM
- Novocure to Report First Quarter 2024 Financial Results • Business Wire • 04/01/2024 11:00:00 AM
- METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長 • Business Wire • 03/29/2024 12:07:00 AM
- Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs • Business Wire • 03/28/2024 05:51:00 PM
- L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives.. • Business Wire • 03/28/2024 05:50:00 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer • Business Wire • 03/27/2024 11:00:00 AM
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO • Business Wire • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:08:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:39:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:56:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:43:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:38:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:35:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:33:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:30:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/22/2024 12:11:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:06:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 12:05:37 PM
- Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update • Business Wire • 02/22/2024 12:00:00 PM
- Novocure Shares Rise 17% After FDA Accepts Pre-Market Application • Dow Jones News • 01/18/2024 04:10:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM